quadgram

This is a table of type quadgram and their frequencies. Use it to search & browse the list to learn more about your study carrel.

quadgram	frequency
severe acute respiratory syndrome	39
for the treatment of	34
acute respiratory distress syndrome	33
efficacy and safety of	31
showed evidence of a	30
acute respiratory syndrome coronavirus	28
in the treatment of	28
chronic obstructive pulmonary disease	27
in the united states	25
in accordance with the	24
first trial of phase	22
evidence of a beneficial	22
food and drug administration	22
the impact of the	22
at the time of	22
as a result of	21
a beneficial effect of	21
of a beneficial effect	21
on the basis of	20
in the context of	20
evidence of a difference	20
in the first trial	19
the end of the	18
a randomized clinical trial	18
the first trial of	18
high risk of bias	18
added to standard care	17
to standard care versus	17
versus standard care alone	17
may need to be	17
as well as the	17
standard care versus standard	17
care versus standard care	17
no evidence of a	17
in the absence of	17
on serious adverse events	16
conduct of clinical trials	16
versus standard care on	16
the world health organization	16
showed no evidence of	16
analysis showed no evidence	16
with acute respiratory failure	16
of a difference between	16
display the preprint in	15
a license to display	15
to display the preprint	15
copyright holder for this	15
holder for this preprint	15
license to display the	15
who has granted medrxiv	15
children with acute respiratory	15
granted medrxiv a license	15
the copyright holder for	15
the trial will be	15
medrxiv a license to	15
the total number of	15
the preprint in perpetuity	15
has granted medrxiv a	15
made available under a	14
remdesivir versus placebo on	14
middle east respiratory syndrome	14
international license it is	14
it is important to	14
willingness to participate in	14
it is made available	14
a randomized controlled trial	14
license it is made	14
is made available under	14
days after randomization in	14
in critically ill patients	13
understanding of the task	13
impact of the pandemic	13
systematic review and meta	13
of chronic obstructive pulmonary	13
after randomization in the	13
in patients with covid	13
the treatment of covid	13
there was no significant	12
neutral with regard to	12
is the author funder	12
with regard to jurisdictional	12
to jurisdictional claims in	12
nature remains neutral with	12
was no significant difference	12
jurisdictional claims in published	12
in a way that	12
maps and institutional affiliations	12
of trial and error	12
preprint this version posted	12
remains neutral with regard	12
at high risk of	12
this preprint this version	12
this version posted june	12
at the end of	12
published maps and institutional	12
springer nature remains neutral	12
for this preprint this	12
in published maps and	12
claims in published maps	12
regard to jurisdictional claims	12
clinical trials during the	11
under a is the	11
a is the author	11
available under a is	11
at the same time	11
and serious adverse events	11
will need to be	11
note springer nature remains	11
d proportion of patients	11
can be found in	10
authors declare that they	10
trials during the covid	10
forest plot and measures	10
declare that they have	10
this paper at https	10
results of a randomized	10
a systematic review and	10
the start of the	10
of this article is	10
inspection of the forest	10
of the forest plot	10
measures to quantify heterogeneity	10
in hospitalized patients with	10
the forest plot and	10
and measures to quantify	10
for treatment of covid	10
need to be considered	10
in the face of	10
as part of the	10
hydroxychloroquine versus standard care	10
of clinical trials in	10
the authors declare that	10
visual inspection of the	10
to ensure that the	10
plot and measures to	10
participate in clinical trials	10
that they have no	10
inclusion and exclusion criteria	10
the conduct of clinical	10
in the control group	10
of clinical trials of	10
straws below the ball	10
to participate in the	10
treatment of patients with	9
relative risk reduction of	9
in adults hospitalized with	9
national institutes of health	9
data and safety monitoring	9
to confirm or reject	9
the efficacy and safety	9
clinical trials of medical	9
time to clinical improvement	9
trials of surfactant in	9
trial sequential analysis showed	9
the impact of covid	9
duration of picu stay	9
of the pandemic on	9
sequential analysis showed that	9
this statement of intent	9
did not cross the	9
on the management of	9
in children with acute	9
us food and drug	9
the three age groups	9
to participate in clinical	9
the severe acute respiratory	9
a relative risk reduction	9
analysis showed that we	9
international clinical trials registry	9
with a relative risk	9
mg kg twice daily	9
the validity of the	9
analysis showed evidence of	9
will be used to	9
trials of medical products	9
clinical trials registry platform	9
study protocol for a	9
for those who cannot	8
adults hospitalized with severe	8
with the aim to	8
care on serious adverse	8
in the experimental group	8
information accompanies this paper	8
of randomised controlled trials	8
analysis of safety data	8
across the three age	8
hospitalized patients with covid	8
of trials in which	8
the results of the	8
a systematic review of	8
systematic reviews and meta	8
all three age groups	8
in light of the	8
analysis of trials of	8
the treatment of patients	8
standard care on serious	8
the us food and	8
by the number of	8
was not possible to	8
of masks and respirators	8
on nonserious adverse events	8
is likely to be	8
of the trial and	8
the course of the	8
a randomised controlled trial	8
impact of the covid	8
it was not possible	8
of medical products during	8
twice daily for days	8
those who cannot take	8
hospitalized with severe covid	8
no significant difference in	8
in the case of	8
within days will be	8
randomized controlled trial of	8
the european medicines agency	8
a serious adverse event	8
of trials of surfactant	8
medical products during covid	8
of clinical trials during	8
surfactant in children with	8
assessed as at high	8
in addition to the	8
in a clinical trial	8
as at high risk	8
supplementary information accompanies this	8
of surfactant in children	8
distrust in pharmaceutical companies	8
accompanies this paper at	8
for the prevention of	8
intermittent preventive treatment of	7
can be used to	7
were assessed as at	7
p r o o	7
a result of the	7
a trial of lopinavir	7
reproduction of this article	7
j o u r	7
days will be assigned	7
unauthorized reproduction of this	7
of malaria in pregnancy	7
and days after randomization	7
of the trial will	7
o u r n	7
on conduct of clinical	7
trial sequential monitoring boundaries	7
be assigned the value	7
this article is prohibited	7
one of the most	7
surfactant was associated with	7
of the pandemic and	7
in the event of	7
the management of clinical	7
they have no competing	7
will be assigned the	7
not included in the	7
proportion of patients with	7
who die within days	7
days number of days	7
in randomised controlled trials	7
patients who die within	7
critically ill patients with	7
free days number of	7
of clinical trials and	7
in the live home	7
randomization in the first	7
a l p r	7
n a l p	7
have no competing interests	7
hospitalised patients with covid	7
trials in developing countries	7
at the university of	7
management of clinical trials	7
quality of life in	7
r o o f	7
adjusted required information size	7
clinical trials in the	7
trial and error behaviour	7
trial and days after	7
of hydroxychloroquine in patients	7
l p r e	7
a review of the	7
die within days will	7
hydroxychloroquine in patients with	7
statistical analysis of safety	7
u r n a	7
duration of mechanical ventilation	7
the time of writing	7
safety and efficacy of	7
r n a l	7
ritonavir in adults hospitalized	7
of remdesivir versus placebo	7
first trial and days	7
of severe acute respiratory	7
there was a significant	7
the first trial and	7
and institutional review boards	7
standard care on all	7
patients with severe covid	7
guidance on conduct of	7
the implementation of the	7
in collaboration with the	7
below the ball and	7
the context of the	7
patients experiencing a serious	6
certainty of the evidence	6
of in the experimental	6
all data will be	6
the first days after	6
who cannot take oral	6
serious adverse event on	6
acute lung injury and	6
type i error of	6
monitoring boundaries for benefit	6
remdesivir for the treatment	6
was calculated based on	6
or before d proportion	6
for benefit or harm	6
boundaries for benefit or	6
patients will be randomized	6
event on or before	6
dexamethasone versus standard care	6
data collection and analysis	6
adverse event on or	6
the case report form	6
updated guidelines for reporting	6
in the design of	6
days within the first	6
is an urgent need	6
the risk of infection	6
trial sequential analysis on	6
general data protection regulation	6
ritonavir versus standard care	6
participants in control group	6
in the second trial	6
before d proportion of	6
the aim of this	6
participate in the trial	6
this article is protected	6
reduction of in the	6
has been shown to	6
of the clinical trial	6
a high level of	6
of days within the	6
placebo on serious adverse	6
effect of remdesivir versus	6
distinction between care and	6
sequential monitoring boundaries for	6
will be performed on	6
for the duration of	6
in the presence of	6
provided with standard supportive	6
the most efficient method	6
cross the trial sequential	6
the green dotted line	6
is protected by copyright	6
pwds and their caregivers	6
with a combination of	6
for reporting parallel group	6
twice daily for those	6
significant difference in the	6
green dotted line shows	6
and type ii error	6
ratio reduction of in	6
in patients with moderate	6
the risk of death	6
article is protected by	6
on the conduct of	6
proactive prophylaxis with azithromycin	6
daily for those who	6
in the field of	6
risk ratio reduction of	6
a member of the	6
the data will be	6
with standard supportive care	6
potential treatments for covid	6
in the developing world	6
prophylaxis with azithromycin and	6
of the evidence was	6
preventive treatment of malaria	6
individual patient data meta	6
are included in the	6
reporting items for systematic	6
randomised controlled trial of	6
proportion of participants in	6
daris was calculated based	6
should be interpreted with	6
parallel group randomised trials	6
adverse events not considered	6
to be able to	6
of participants in control	6
experiencing a serious adverse	6
iv twice daily for	6
protection of human subjects	6
required information size was	6
in hospitalised patients with	6
efficacy of hydroxychloroquine in	6
of lopinavir ritonavir and	6
reporting parallel group randomised	6
of novel coronavirus pneumonia	6
within the first days	6
the control group of	6
the trial sequential monitoring	6
proportion of patients experiencing	6
type ii error of	6
dotted line shows conventional	6
international conference on harmonisation	6
line shows conventional boundaries	6
there is an urgent	6
between d and d	6
not be able to	6
the university of oxford	6
guidelines for reporting parallel	6
not possible to perform	6
the use of hydroxychloroquine	6
of patients experiencing a	6
the acute respiratory distress	6
trial and error is	6
the required information size	6
guidance on the management	6
in the case report	6
first days after enrollment	6
trials were assessed as	6
acute exacerbation of copd	6
the same action sequence	6
on or before d	6
randomization in the second	6
not cross the trial	6
exacerbations of chronic obstructive	6
versus placebo on serious	6
the extent to which	6
on the use of	6
preferred reporting items for	6
who international clinical trials	6
a large number of	6
for the purpose of	6
number of days within	6
the who international clinical	6
on adverse events not	6
the daris was calculated	6
beneficial effect of remdesivir	6
to make a choice	6
research involving human subjects	5
events with a relative	5
the workshop on trade	5
whether or not the	5
of this study is	5
phase ii trials are	5
the standard care group	5
to changing task demands	5
of the task and	5
enough information to confirm	5
this is the first	5
common terminology criteria for	5
a retrospective cohort study	5
in a number of	5
showed that we did	5
lack of relevant data	5
workshop on trade and	5
the trial emulation framework	5
the duration of the	5
pangolins native to south	5
or nonserious adverse events	5
the k th stage	5
and reporting data for	5
the intensive care unit	5
with azithromycin and chloroquine	5
payment for research participation	5
of the pandemic in	5
did not have enough	5
of the trial design	5
azithromycin and chloroquine in	5
patients and reporting data	5
trade and conservation of	5
in patients treated with	5
of a randomized clinical	5
need for mechanical ventilation	5
number of confirmed cases	5
the study will be	5
randomizing patients and reporting	5
beneficial effect of standard	5
analysis and reporting of	5
patients in clinical trials	5
severe acute respiratory distress	5
conservation of pangolins native	5
a combination of lopinavir	5
for the use of	5
in proceedings of the	5
due to the pandemic	5
of clinical trials for	5
as well as a	5
a living mapping of	5
are eligible for inclusion	5
the false discovery rate	5
information to confirm or	5
of this study was	5
effectiveness and safety of	5
for the protection of	5
in the pooled analysis	5
in the dexamethasone group	5
between care and research	5
be interpreted with caution	5
patients do not receive	5
in the standard care	5
we did not have	5
participation in the trial	5
interventions for treatment of	5
trials and observational studies	5
bubonic or pneumonic plague	5
a living systematic review	5
of a phase iii	5
adverse events with a	5
kg twice daily for	5
events not considered serious	5
the use of masks	5
mg orally twice daily	5
will be reported as	5
cause mortality and serious	5
trial and error and	5
of randomized controlled trials	5
during the intervention period	5
proceedings of the workshop	5
do not receive of	5
through trial and error	5
the quality of life	5
is associated with a	5
you get the ball	5
the main limitation of	5
lopinavir ritonavir and interferon	5
and conservation of pangolins	5
a difference between lopinavir	5
in the number of	5
proportion of patients who	5
resource utilization in dementia	5
end of the study	5
intermittent preventive treatment with	5
in the academic literature	5
of a harmful effect	5
consent to participate in	5
as one of the	5
if the patient is	5
and chloroquine in hospitalised	5
trial and error may	5
related to the pandemic	5
not have enough information	5
the majority of the	5
principles for clinical trials	5
a phase iii trial	5
their first trial of	5
first presented with the	5
of the impact of	5
randomised evaluation of covid	5
in the pharmaceutical industry	5
trials related to covid	5
the number of trials	5
after enrollment when patients	5
phase ii trials may	5
with a deviated septum	5
to south and southeast	5
evidence of a harmful	5
the united states food	5
the protection of human	5
and trial sequential analyses	5
moderate to severe psoriasis	5
outcome was assessed days	5
clinical trials in korea	5
and healthcare products regulatory	5
effect of hydroxychloroquine on	5
conducted in accordance with	5
at d proportion of	5
days after enrollment when	5
more than one trial	5
prevention and treatment of	5
of the study is	5
and institutional affiliations we	5
of the primary outcome	5
south and southeast asia	5
assessed days after randomization	5
fda guidance on conduct	5
university of medical sciences	5
of clinical research in	5
native to south and	5
risks of systematic errors	5
the primary outcome measure	5
that we did not	5
statistical principles for clinical	5
trial randomizing participants compared	5
being repurposed for covid	5
versus placebo on all	5
of safety data in	5
in the setting of	5
analyses and trial sequential	5
on trade and conservation	5
serious adverse events in	5
of good clinical practice	5
during a pandemic is	5
there is a need	5
used the same action	5
clinical trials on covid	5
have enough information to	5
combination of lopinavir ritonavir	5
the standard of care	5
medicines and healthcare products	5
randomized clinical trials during	5
course of the covid	5
when patients do not	5
of the reviewed trials	5
of pangolins native to	5
for the management of	5
the rest of the	5
effect of standard care	5
terminology criteria for adverse	5
with dementia and their	5
united states food and	5
chloroquine in hospitalised patients	5
healthcare products regulatory agency	5
the outcome was assessed	5
the statistical analysis plan	5
the safety and efficacy	5
the proportion of patients	5
by the research team	5
the participants will be	5
states food and drug	5
confirm or reject that	5
the primary outcome is	5
were included in the	5
and safety monitoring board	5
use of a respirator	5
for the first time	5
with respect to the	5
effect of age on	5
mortality and serious adverse	5
in patients with severe	5
criteria for adverse events	5
mashhad university of medical	5
was assessed days after	5
reporting data for patients	5
reduced the risk of	5
enrollment when patients do	5
head and neck cancer	5
will be carried out	5
the median number of	5
trial is funded by	5
end of the trial	5
treatment of malaria in	5
patient willingness to participate	5
with severe acute respiratory	5
of the workshop on	5
short period of time	4
in order to identify	4
are able to swallow	4
by gautret et al	4
the statistical analysis of	4
results of the trial	4
action sequences in phase	4
of adverse events in	4
centers for disease control	4
the miracle trial is	4
during the current pandemic	4
or once deemed clinically	4
causal understanding of the	4
for randomized clinical trials	4
the declaration of helsinki	4
it is imperative that	4
may switch to oral	4
the location of the	4
an event rate in	4
for the success of	4
in a timely manner	4
experience with the task	4
max mg per dose	4
to the study treatment	4
that can be delivered	4
accessible from the trials	4
cohorts and routinely collected	4
based on an event	4
the introduction of new	4
reject realistic intervention effects	4
are assigned a coefficient	4
geriatric clinical trials research	4
for all three age	4
and remdesivir might be	4
a deviated nasal septum	4
included in this study	4
at the individual level	4
in high risk of	4
authors would like to	4
the results from the	4
an equal number of	4
a randomized trial of	4
for people with dementia	4
increase in antibody titre	4
the safety profile of	4
protocol for a randomized	4
protocol for a randomised	4
the interest in expediting	4
a difference between convalescent	4
across all trials in	4
attached as an additional	4
the change in task	4
a measure of the	4
serious adverse events with	4
may be difficult to	4
numbers to be randomised	4
was associated with more	4
that dexamethasone and remdesivir	4
of missing data and	4
might be beneficial for	4
risk of bias trials	4
when there is a	4
the development of new	4
ciprofloxacin mg kg twice	4
were included in this	4
the number of covid	4
the national institutes of	4
the data monitoring committee	4
expediting dissemination of this	4
evidence was low to	4
the trial steering committee	4
is based on the	4
an immunological correlate of	4
a sample size of	4
received approval from the	4
patients admitted to hospital	4
that we had enough	4
in the statistical analysis	4
clinical research in the	4
will be transferred to	4
dissemination of this material	4
in the united kingdom	4
on the other hand	4
live oral cholera vaccine	4
an important role in	4
plasma versus standard care	4
there may be a	4
the remainder of the	4
chloroquine phosphate has shown	4
protocol is attached as	4
the number of confirmed	4
pneumonia in clinical studies	4
is attached as an	4
event rate in the	4
when first presented with	4
in their first trial	4
in the time of	4
with mild to moderate	4
rate in the control	4
trial and error process	4
due to lack of	4
significant effect of age	4
the management of the	4
switch to oral administration	4
clinical characteristics of coronavirus	4
interventions to interrupt or	4
within days of the	4
azithromycin as a treatment	4
haemophilus influenzae type b	4
reduce the need for	4
approved the final manuscript	4
named severe acute respiratory	4
the relative stress scale	4
convalescent plasma versus standard	4
access to the full	4
the included trials were	4
the safety of the	4
east respiratory syndrome coronavirus	4
adults with severe covid	4
conduct of the study	4
dexamethasone in hospitalized patients	4
of health and human	4
should be given to	4
assigned a coefficient of	4
of systematic errors and	4
will receive placebo plus	4
whether or not they	4
in the sense of	4
department of health and	4
we identified trials comparing	4
proportion of trials that	4
in adults with severe	4
for systematic reviews and	4
with acute respiratory distress	4
for disease control and	4
one single trial randomizing	4
deemed clinically appropriate by	4
the authors would like	4
recorded in the case	4
hydroxychloroquine and azithromycin as	4
be beneficial for covid	4
the primary objective of	4
to interrupt or reduce	4
the beginning of the	4
consideration should be given	4
trial efficacy and safety	4
can be delivered by	4
by the treating physician	4
as soon as the	4
and azithromycin as a	4
septoplasty versus medical management	4
patients admitted to the	4
as soon as possible	4
characteristics of coronavirus disease	4
results of an open	4
with moderate to severe	4
dexamethasone and remdesivir might	4
the certainty of the	4
of the full protocol	4
assessing the impact of	4
of critically ill patients	4
at the second stage	4
trials showed evidence of	4
clinical trials for covid	4
systematic reviews of interventions	4
disease control and prevention	4
of patients infected with	4
clinical trials during covid	4
the full protocol is	4
the quintet recruitment intervention	4
able to swallow or	4
mean difference in score	4
assess the impact of	4
and trial sequential analysis	4
of the severe acute	4
difference between remdesivir versus	4
no conflict of interest	4
for patients with severe	4
trial will be conducted	4
of coronavirus disease in	4
high quality clinical trials	4
has shown apparent efficacy	4
and whether or not	4
seroconversion or a fourfold	4
the data protection act	4
more trials are needed	4
formatting has been eliminated	4
had enough information to	4
three age groups of	4
interrupt or reduce the	4
in the interest in	4
their time and effort	4
the straw directly below	4
mg kg iv twice	4
of the trial in	4
fourfold increase in antibody	4
from the trials website	4
the familiar formatting has	4
adverse events in high	4
in a timely fashion	4
would need to be	4
data in clinical trials	4
interest in expediting dissemination	4
a significant effect of	4
cause mortality with a	4
of acute lung injury	4
reduce the spread of	4
in practice in the	4
or a fourfold increase	4
for the scientific community	4
as an additional file	4
death and serious adverse	4
efficacy in treatment of	4
clinical trials should be	4
that trial and error	4
in order to overcome	4
assess the effect of	4
information to reject that	4
of the key elements	4
in which children made	4
living systematic review with	4
the treatment of chronic	4
to the conduct of	4
the spread of respiratory	4
impact on the trial	4
kg iv twice daily	4
remdesivir might be beneficial	4
standard of care arm	4
we had enough information	4
or reduce the spread	4
research council of norway	4
was a significant negative	4
based on in vitro	4
in cancer clinical trials	4
in terms of timing	4
will be invited to	4
will likely need to	4
apparent efficacy in treatment	4
associated with more ventilator	4
will be recorded in	4
to find the food	4
an index score of	4
physical interventions to interrupt	4
use of rescue therapy	4
mortality with a relative	4
so more trials are	4
or mg kg iv	4
a summary of the	4
or reject realistic intervention	4
as a summary of	4
between convalescent plasma versus	4
during this pandemic has	4
beneficial effect of dexamethasone	4
the pandemic of covid	4
is no specific treatment	4
clinically appropriate by the	4
the development of the	4
our aim was to	4
due to contact with	4
followed by ciprofloxacin mg	4
influenza transmission in households	4
between remdesivir versus placebo	4
underpowered to confirm or	4
chloroquine with or without	4
by the world health	4
half of the trials	4
use during the covid	4
clinical trials in developing	4
in treatment of covid	4
to the patient and	4
a fourfold increase in	4
to participate in different	4
a total of patients	4
in expediting dissemination of	4
if there is a	4
all authors contributed to	4
as a treatment of	4
coronavirus named severe acute	4
that there was a	4
reducing the risk of	4
is caused by the	4
phosphate has shown apparent	4
of the lack of	4
use of remdesivir for	4
will be published in	4
of standard care on	4
shown apparent efficacy in	4
analysis will be conducted	4
will be provided with	4
receive jwby formulas plus	4
of human subjects of	4
central statistical monitoring of	4
of immune responses in	4
of medical journal editors	4
serves as a summary	4
enough information to reject	4
elements of the full	4
during the coronavirus pandemic	4
was low to very	4
were underpowered to confirm	4
in patients with dementia	4
remdesivir in adults with	4
as early as possible	4
the findings of the	4
and approved the final	4
and the impact of	4
malaria chemoprevention in pregnancy	4
the pwd and the	4
mg kg every h	4
calculated based on an	4
events in high risk	4
adverse events in the	4
action sequence was used	4
to retrieve the ball	4
the duration of picu	4
used the most efficient	4
by severe acute respiratory	4
it is not possible	4
to complete their first	4
of serious adverse events	4
once deemed clinically appropriate	4
authors read and approved	4
with or without a	4
swallow or once deemed	4
assessing the effects of	4
during the study period	4
the international conference on	4
respiratory distress syndrome in	4
macrolide for treatment of	4
primary and secondary outcomes	4
olds made efficient responses	4
they are able to	4
than the younger children	4
the final cumulative network	4
showed that we had	4
key elements of the	4
the majority of trials	4
of the trials were	4
benefits and harms of	4
while on the go	4
the evidence base for	4
early phase clinical trials	4
spread of respiratory viruses	4
access to clinical trials	4
confirm or reject realistic	4
a harmful effect of	4
straw directly below the	4
that there is a	4
the purpose of this	4
on the impact of	4
study of hydroxychloroquine in	4
once they are able	4
we believe that the	4
appropriate by the treating	4
trials were included in	4
read and approved the	4
on quality of life	4
spontaneous understanding of the	4
small cell lung cancer	4
significant negative correlation between	4
of septoplasty versus medical	4
stable chronic obstructive pulmonary	4
in relation to the	4
at the start of	4
letter serves as a	4
in treatment of patients	4
was associated with a	4
routinely collected health data	4
the conditions for each	4
to oral administration once	4
based treatment for covid	4
in contrast to phase	4
of hydroxychloroquine in hospitalized	4
have an impact on	4
of the study and	4
for good clinical practice	4
change in task configuration	4
distrust in the pharmaceutical	4
to assess the impact	4
on an event rate	4
start of the trial	4
but the certainty of	4
on behalf of the	4
coronavirus disease in china	4
use of masks and	4
nasal high flow therapy	4
the type i error	4
the effects of the	4
pwd and the caregiver	4
will receive jwby formulas	4
to be associated with	4
items for systematic reviews	4
summary of the key	4
to swallow or once	4
g of dead ants	4
and safety monitoring boards	4
there is no specific	4
revealed that there was	4
the benefits and harms	4
and routinely collected health	4
it is difficult to	4
six trials randomizing patients	4
administration once they are	4
randomized clinical trial hydroxychloroquine	4
a difference between remdesivir	4
practice in the live	4
are available from the	4
full protocol is attached	4
the primary outcome of	4
a treatment of covid	4
complete their first trial	4
jia wei bushen yiqi	4
is the total number	4
the evidence was low	4
the change of the	4
clinical trials related to	4
the conduct of the	4
the key elements of	4
data safety monitoring board	4
patients with moderate to	4
patients with bubonic plague	4
the proportion of trials	4
all trials in phase	4
implementation of the intervention	4
this letter serves as	4
median survival of days	4
the quality of the	4
all authors read and	4
conducting clinical trials in	4
were not included in	4
duration of the trial	4
difference between convalescent plasma	4
harmful effect of hydroxychloroquine	4
age groups of children	4
a high incidence of	4
none of the trials	4
for the development of	4
patients with acute respiratory	4
the national cancer institute	4
the most efficient solution	4
are likely to be	4
conduction of clinical trials	4
over half of the	4
low to very low	4
see supplementary video s	4
a significant negative correlation	4
trials randomizing patients and	4
acute generalized exanthematous pustulosis	4
to evaluate the efficacy	4
in the era of	4
medical research involving human	4
remdesivir for patients with	4
will be randomized to	4
associated pneumonia in clinical	4
the treatment policy strategy	4
of remdesivir for patients	4
oral administration once they	4
familiar formatting has been	4
the authors declare no	4
important to note that	4
be of interest for	4
to severe acute respiratory	4
using cohorts and routinely	4
is not possible to	4
novel coronavirus named severe	4
x x x x	4
there has been a	4
were all at risks	3
colchicine added to standard	3
but there was no	3
estimates of vaccine protection	3
was associated with increased	3
in nursing home patients	3
of chloroquine diphosphate as	3
of treatment and for	3
the general data protection	3
the number of participants	3
an update on the	3
systematically search the platform	3
the gender gap in	3
timing related to the	3
the success of an	3
drugs for malaria prevention	3
of chloroquine for the	3
how users use it	3
remote access to electronic	3
for the pwd will	3
registered before the peak	3
this study was to	3
chimpanzees and gorillas tested	3
the use of an	3
of the vaccine candidate	3
being committed to other	3
for rcts using cohorts	3
be more effective than	3
be conducted in accordance	3
sunda pangolin manis javanica	3
innovative clinical trial designs	3
to placebo provided with	3
is a member of	3
our living systematic review	3
or publication of this	3
use of masks in	3
for a single cohort	3
the main trial will	3
by the international conference	3
tested in developing countries	3
be released to the	3
hospitalized with severe acute	3
the reduce randomized clinical	3
trials in which children	3
in the management of	3
with metastatic colorectal cancer	3
of the study will	3
doses of chloroquine diphosphate	3
on top of a	3
treatment medications are based	3
the average weight of	3
part of the trial	3
may not be able	3
experienced by the caregiver	3
the analysis of safety	3
aim of this study	3
in public health practice	3
acute exacerbations of copd	3
that aim to investigate	3
as a form of	3
specific treatment or vaccination	3
reporting systematic reviews and	3
treatment of patients admitted	3
characteristics of cases of	3
as adjunctive therapy for	3
perform high quality clinical	3
for children with cancer	3
tasks or quarantining themselves	3
from the corresponding author	3
admitted to hospital with	3
be found in table	3
in health care workers	3
at risks of systematic	3
preserving clinical trial integrity	3
on in vitro laboratory	3
involved in clinical trials	3
mitigation measures influence the	3
to dexamethasone versus standard	3
it would be interesting	3
would be interesting to	3
a case study of	3
to prevent influenza transmission	3
around the world are	3
in clinical trials the	3
is the use of	3
the trial and error	3
in clinical trials of	3
no serious adverse events	3
reasons for this include	3
participants who wish to	3
it is assumed that	3
of all treatment interventions	3
the ball and three	3
committee of medical journal	3
worn continually during a	3
is defined as the	3
more effective than hand	3
the norwegian national advisory	3
in a trial of	3
treatment of novel coronavirus	3
over the course of	3
the patient and the	3
that there is no	3
extracted data and assessed	3
be the case for	3
of patients with a	3
lopinavir ritonavir plus interferon	3
the clinical trial is	3
in the area of	3
will be required for	3
will have access to	3
their efficiency in phase	3
a wide range of	3
start and stop dates	3
action sequences that were	3
the required sample size	3
a pathway for dementia	3
ciprofloxacin mg orally twice	3
on cognitive decline in	3
to the course of	3
trials during this pandemic	3
masks and respirators against	3
medications are based on	3
the absence of a	3
as a proportion of	3
of hydroxychloroquine in covid	3
has the potential to	3
will be collected at	3
hydroxychloroquine or chloroquine with	3
that the pangolin could	3
summary of a study	3
hospitalized patients with severe	3
an urgent need to	3
clinical trials during pandemics	3
clinical trial integrity during	3
of patients to be	3
whether the patient has	3
as well as medical	3
for an additional days	3
knew the name of	3
a difference on our	3
or not they would	3
pediatric risk of mortality	3
the randomised evaluation of	3
are randomly assigned to	3
the conclusion of the	3
that the window of	3
or quarantining themselves due	3
the prospect of direct	3
refusal to participate in	3
included trials were all	3
is more important than	3
from a variety of	3
rcts evaluating preventive interventions	3
with standard care reduces	3
enhanced use of it	3
will be conducted at	3
the conventional naive boundaries	3
treatments for coronavirus disease	3
also referred to as	3
in treating similar viruses	3
registered in the who	3
have the opportunity to	3
to contact with covid	3
performed a living mapping	3
a total of covid	3
external to the trial	3
use of the device	3
the university of bergen	3
hydroxychloroquine in hospitalized patients	3
this was not the	3
the danish medicines agency	3
when they were able	3
randomised controlled trials in	3
barriers relate to health	3
of the editorial board	3
be used to compare	3
other it and non	3
a public health emergency	3
patients who meet the	3
in spite of the	3
is a need for	3
of the total trial	3
as a function of	3
and randomized clinical trials	3
research during the covid	3
a multinational registry analysis	3
negative correlation between their	3
the prevention and treatment	3
red outward sloping lines	3
we will use the	3
healthy life trajectories initiative	3
results but were underpowered	3
randomized controlled trials in	3
the north american trials	3
repeatedly removing the straw	3
flexible due to high	3
the outcome of the	3
clinical research of covid	3
staff involved in the	3
treating similar viruses such	3
and its effects on	3
pandemic is affected at	3
make use of it	3
in vitro laboratory investigations	3
to such external unplanned	3
an analysis of the	3
in health care settings	3
ii trials may also	3
the media briefing on	3
treatment and clinical research	3
may be needed for	3
lack of efficacy or	3
institutional affiliations we thank	3
as days alive and	3
authors contributed to the	3
by consensus in consultation	3
this living systematic review	3
possible action sequences that	3
clinical characteristics of cases	3
as much as possible	3
systematic errors and random	3
with nasal high flow	3
used an efficient action	3
for six trials randomizing	3
a trial should be	3
informed consent always necessary	3
the ards network study	3
death due to covid	3
study is to investigate	3
report a trial of	3
of the intervention will	3
possibility of undue influence	3
conduct of clinical research	3
adverse events were reported	3
they are asked to	3
the field of oncology	3
the action sequences used	3
confirmed probable bubonic plague	3
to streptomycin plus ciprofloxacin	3
in policy trial emulation	3
will be needed to	3
of hydroxychloroquine with azithromycin	3
time points varied from	3
in the conduction of	3
and reduced the duration	3
will be treated with	3
involved in the conduction	3
this trial will be	3
difference across the three	3
of clinical trial research	3
and both together are	3
health and human services	3
in more than one	3
international conference on harmonization	3
code of federal regulations	3
all trials were assessed	3
be tested in developing	3
the probability that a	3
the unit of analysis	3
have access to the	3
patients with lung cancer	3
was not the case	3
for other types of	3
will be sent to	3
rcts using cohorts and	3
action sequences used by	3
continue investigative treatments due	3
data from clinical trials	3
in research activities to	3
is the maximum probability	3
who cannot take it	3
continually during a shift	3
us national institutes of	3
half of the sites	3
none of the remaining	3
clinical trial during the	3
a rich description of	3
of participants as well	3
clinical development of a	3
to address the issues	3
to electronic medical records	3
development of a vaccine	3
the trial has been	3
there has been no	3
access to public places	3
trial integrity during the	3
task is experienced by	3
approval and consent to	3
that need to be	3
eight test and four	3
trial of awake prone	3
informed consent was obtained	3
take into account the	3
before and after the	3
has not been addressed	3
therapy for patients hospitalized	3
both personal and professional	3
will be compared against	3
a minimum of two	3
the nordic cochrane centre	3
or advisory role for	3
effect of dexamethasone on	3
consent based on their	3
efficacy at the second	3
of patients in clinical	3
their initial negative disconfirmation	3
the intervention group will	3
media briefing on covid	3
may be used to	3
effect of high vs	3
and time constraints needed	3
affected at multiple levels	3
or chloroquine with or	3
red outward sloping red	3
that the majority of	3
to assess the effect	3
in order to determine	3
malarial drugs in pregnancy	3
for clinical trials in	3
reduced the duration of	3
reporting of clinical trials	3
malaria prevention during pregnancy	3
at the media briefing	3
whether the patient is	3
the inclusion and exclusion	3
available for six trials	3
in the same way	3
like to acknowledge the	3
adult respiratory distress syndrome	3
was days after randomization	3
and in need for	3
for adults with a	3
the methods used to	3
in the event that	3
errors and random errors	3
the need for a	3
of the live home	3
influenza a h n	3
which was first detected	3
is of utmost importance	3
and safety of apremilast	3
of interest for the	3
in the surgical arm	3
due to high contagiousness	3
suggested treatment medications are	3
for researchers to conduct	3
concerns about undue influence	3
minimal clinically important difference	3
recruitment bias in clinical	3
questionnaire on cognitive decline	3
the best research approaches	3
standards of reporting trials	3
acute ischemic stroke and	3
a pandemic is affected	3
will be included as	3
based on standard cut	3
known to be associated	3
to withdraw from the	3
of the vaccine strain	3
a randomised clinical trial	3
during the first trial	3
is a lack of	3
status of surgical clinical	3
to take into account	3
in a similar manner	3
the effects of remdesivir	3
for patients hospitalized with	3
with rsv severe bronchiolitis	3
national institute for health	3
intention to treat infected	3
alone or in combination	3
brain of the tree	3
of middle east respiratory	3
as defined by the	3
will be important to	3
ethical principles for medical	3
principles for medical research	3
standard of care and	3
for both personal and	3
of high vs low	3
medical management for adults	3
conducted according to the	3
and observational studies of	3
initiated during the pandemic	3
the large number of	3
of the tree pangolin	3
approaches are those that	3
no specific treatment or	3
trials during a pandemic	3
to receive the vaccine	3
there is a clear	3
bias in clinical trials	3
use of hydroxychloroquine for	3
would like to acknowledge	3
the informed consent process	3
and natural history of	3
inability to continue investigative	3
dwelling people with dementia	3
need of treatment and	3
in severe acute respiratory	3
will be used for	3
extension for rcts using	3
septoplasty with or without	3
or individual patient data	3
next of kin or	3
possible to perform other	3
different categories of clinical	3
four straws below the	3
ministry of health and	3
in consultation with a	3
theory of trial and	3
serious adverse events were	3
is also possible that	3
if it is not	3
of this vaccine in	3
and in this case	3
single trial randomizing participants	3
phase iii trials may	3
this study is to	3
for systematic reviews of	3
integrity during the coronavirus	3
based on their determination	3
compared with standard care	3
clinical trials in a	3
for reporting systematic reviews	3
or other retroviral infections	3
of surgical clinical trials	3
high vs low doses	3
alive and out of	3
to day and day	3
together are more protective	3
to perform high quality	3
malarial drug for malaria	3
will be asked to	3
sequential analysis on remdesivir	3
and out of hospital	3
responses in the first	3
institute for health research	3
more likely to be	3
the next of kin	3
free days to day	3
and flexible due to	3
we performed a living	3
analyzed during the current	3
total of patients with	3
add to our understanding	3
caused by the novel	3
the platform every week	3
of health and care	3
will continuously inform best	3
consensus in consultation with	3
a potent inhibitor of	3
of the action sequences	3
monitoring of data quality	3
studies looking at the	3
of timing related to	3
on remdesivir versus placebo	3
after the end of	3
health and care services	3
an efficient action sequence	3
be used to assess	3
had at least one	3
registry of clinical trials	3
or inability to continue	3
coronavirus pneumonia in wuhan	3
days alive and out	3
in the intensive care	3
the time of covid	3
and the effectiveness of	3
treatment or vaccination for	3
is in the intervention	3
structured summary of a	3
during the current study	3
is characterized by a	3
trials that aim to	3
of integrative cancer therapies	3
positioning with nasal high	3
the number of clinical	3
withdraw from the trial	3
statistically significant results but	3
first detected in wuhan	3
impact of missing data	3
needed to perform high	3
associated with a deviated	3
clinical trials conducted in	3
prevention of gastrointestinal bleeding	3
care professionals being committed	3
of our empirical material	3
at the very least	3
care alone showed evidence	3
of two home visits	3
a difference between hydroxychloroquine	3
admitted to intensive care	3
of activated protein c	3
in routine clinical practice	3
inward sloping red lines	3
it is possible to	3
provide written informed consent	3
the interpretability of the	3
in the form of	3
patients in each group	3
on the identification of	3
not be the case	3
the informant questionnaire on	3
treatment of bubonic plague	3
for trials alongside genv	3
and or publication of	3
because of the lack	3
clinical trials have been	3
of patients with acute	3
decline in the elderly	3
three age groups in	3
phase iii randomized controlled	3
for acute respiratory failure	3
is defined as follows	3
the use of a	3
unit on ageing and	3
at least a single	3
between hydroxychloroquine versus standard	3
growing body of evidence	3
at the beginning of	3
it is necessary to	3
the results of a	3
participant continues to adhere	3
assessment time points varied	3
in the placebo group	3
and institutional affiliations the	3
to perform other meta	3
professional and personal use	3
participants as well as	3
of dexamethasone in hospitalized	3
consists of blog posts	3
to other critical tasks	3
to the full protocol	3
it is possible that	3
adults with a deviated	3
vs low doses of	3
pharmaceuticals for human use	3
clinical trial designs in	3
a hypothetical strategy for	3
respirators for healthcare workers	3
in pharmaceutical companies is	3
parents of all newborns	3
controlled trial a randomized	3
current pandemic of coronavirus	3
interest for the primary	3
to the eligible trials	3
within the context of	3
sensory information about the	3
included in this review	3
placebo provided with standard	3
will be followed up	3
single trials showed statistically	3
the patients will be	3
the research council of	3
management for adults with	3
workers and sick patients	3
on masks and respirators	3
what matters to you	3
the design of the	3
the ball from the	3
the first interim analysis	3
available under a author	3
currently registered clinical trials	3
informed consent to research	3
ciprofloxacin mg twice daily	3
the conduction of clinical	3
infection prevention and control	3
standard care reduced the	3
malarial drugs for malaria	3
by the novel coronavirus	3
interim analysis will be	3
have agreed to participate	3
be considered as ices	3
to our understanding of	3
research approaches are those	3
both together are more	3
the effectiveness and safety	3
participant in the trial	3
users are able to	3
the trial and the	3
to the intensive care	3
in december is caused	3
of a difference on	3
diphosphate as adjunctive therapy	3
of awake prone positioning	3
source register unique identifier	3
important during the covid	3
development and validation of	3
to comply with the	3
versus medical management for	3
the dexamethasone group compared	3
pandemic has not been	3
in the clinical trial	3
alone showed evidence of	3
of cases of novel	3
we identified one trial	3
of at least one	3
professionals being committed to	3
a recent study of	3
advisory unit on ageing	3
observational studies of single	3
study was to review	3
of the coronavirus disease	3
declare no competing interests	3
total number of patients	3
adapt to such external	3
looking at the long	3
role in the design	3
which was not certified	3
cancer patients in sars	3
reject that remdesivir versus	3
ensure that the window	3
influence the course of	3
is a risk of	3
no increased risk of	3
on a vertical plane	3
related to the course	3
critical tasks or quarantining	3
on the trial results	3
wedge cluster randomised trial	3
informant questionnaire on cognitive	3
prior to the trial	3
cleaning and database lock	3
it may not be	3
committed to other critical	3
or limited access to	3
trials assessing the effects	3
observed in the trial	3
lopinavir ritonavir and recombinant	3
used different interventions and	3
the treatment of severe	3
for the novel coronavirus	3
were approved by the	3
as a random effect	3
of the effect of	3
the treatment of bubonic	3
the probability of missingness	3
the west africa ebola	3
more important than ever	3
cov infection treated with	3
it has been shown	3
standard care on adverse	3
will be presented as	3
the number of straws	3
in the clinical study	3
investigative treatments due to	3
standard care alone showed	3
care on adverse events	3
average trial completion latency	3
which was not peer	3
final approval of the	3
in clinical trials in	3
included in the analysis	3
their interaction with the	3
a single dose of	3
to high contagiousness of	3
themselves due to contact	3
dementia and their caregivers	3
will be reported to	3
safety of participants and	3
for this include patient	3
reduce randomized clinical trial	3
the context of a	3
redundancy in research questions	3
curve did not cross	3
cases of novel coronavirus	3
best management strategy for	3
and nonserious adverse events	3
suspected unexpected serious adverse	3
the best management strategy	3
the ball and one	3
quadrivalent rhesus rotavirus reassortant	3
out different things in	3
infection treated with a	3
in using the tablet	3
best practice in treatment	3
the clinical study nurse	3
the maximum probability threshold	3
of the it device	3
too many walls and	3
be reported as a	3
evaluated the impact of	3
quarantining themselves due to	3
number of adverse events	3
analysis of the primary	3
chemoprevention in pregnancy trials	3
respiratory failure in children	3
awake prone positioning with	3
with respiratory syncytial virus	3
will be assessed by	3
walls and ceilings to	3
has been used to	3
be transferred to the	3
practice in treatment and	3
quality of life and	3
that may lead to	3
will be released to	3
did you do that	3
health care professionals being	3
definition of therapeutic response	3
compassionate use of remdesivir	3
a variety of causes	3
there is a growing	3
countries as well as	3
consultation with a third	3
the integrity of the	3
the containers were placed	3
described in detail in	3
constraints needed to perform	3
a way that is	3
as well as in	3
before the formal clinical	3
this include patient hesitancy	3
a study protocol for	3
of the data and	3
possible to perform meta	3
universal face mask use	3
changes in the system	3
results on the registry	3
location of the ball	3
consort extension for rcts	3
the treatment of moderate	3
comprehensive trial coordination mechanisms	3
type of test trial	3
the characteristics of the	3
nationwide analysis in china	3
with the kcdc guideline	3
adhere to study treatment	3
of interventional trials from	3
certified by peer review	3
the duration of ventilation	3
a structured summary of	3
mild to moderate covid	3
the possibility of a	3
dexamethasone group compared with	3
of traditional chinese medicine	3
may be associated with	3
the formal clinical trial	3
and there is a	3
to the use of	3
it is unlikely that	3
china clinical course and	3
the efficacy of a	3
trial of intravenous immunoglobulin	3
include patient hesitancy or	3
limited access to public	3
continuously inform best practice	3
minimum of two home	3
oral cholera vaccine cvd	3
in need for mechanical	3
wedge randomized control design	3
that remdesivir versus placebo	3
similar viruses such as	3
with the principles of	3
is affected at multiple	3
in treatment and clinical	3
the effect of covid	3
systematic review of the	3
the results suggest that	3
patient hesitancy or inability	3
on day and on	3
will be conducted on	3
of the suggested treatment	3
of a study protocol	3
the control group will	3
epidemiological and clinical characteristics	3
difference on our predefined	3
the salk polio vaccine	3
difference between hydroxychloroquine versus	3
care reduced the risk	3
or analyzed during the	3
all treatment interventions for	3
wedge randomized controlled trial	3
a small number of	3
the type of trial	3
the window of opportunity	3
of the trial results	3
this trial showed evidence	3
and for researchers to	3
to evaluate the impact	3
regarding the use of	3
trial intermittent preventive treatment	3
the small sample size	3
to clinical improvement as	3
it is also possible	3
the international committee of	3
of the primary completion	3
the identification of a	3
there is no evidence	3
opening remarks at the	3
their level of trust	3
relate to health care	3
not good enough or	3
to participate in trials	3
ontologies with controlled vocabularies	3
order to overcome it	3
with nasal obstruction associated	3
adequately powered multicentre trials	3
remarks at the media	3
main limitation of this	3
december is caused by	3
the end of each	3
no significant difference across	3
a added to standard	3
increase in the number	3
ensuring patient safety and	3
obstruction associated with a	3
measures influence the course	3
design and conduct of	3
our results show that	3
not if worn intermittently	3
as long as the	3
number of registered trials	3
exclude the possibility of	3
the principle of autonomy	3
the department of health	3
different things in order	3
used an efficient solution	3
the suggested treatment medications	3
review will continuously inform	3
be randomized using a	3
b provided with standard	3
today there is no	3
consolidated standards of reporting	3
from baseline to day	3
effects of all treatment	3
chloroquine for the treatment	3
the length of hospitalisation	3
intravenous vitamin c in	3
might need to be	3
obstructive pulmonary disease in	3
there is a risk	3
surgical clinical trials during	3
was baited with food	3
the pwd will be	3
will take place in	3
at the conclusion of	3
community use of masks	3
when task demands changed	3
data will be collected	3
be included in the	3
time constraints needed to	3
patients with rsv severe	3
patient distrust in the	3
in order to keep	3
always necessary for randomized	3
affected by the pandemic	3
released to the participating	3
handling of missing data	3
for which there is	3
data from the trial	3
the technology acceptance model	3
how burdensome the task	3
a different action sequence	3
is important to note	3
in bradford better start	3
the study and the	3
pandemic of coronavirus disease	3
or vaccination for sars	3
most of the suggested	3
and error and outcomes	3
the london school of	3
context of the pandemic	3
adhere to the study	3
access to electronic medical	3
of the most important	3
that hydroxychloroquine versus standard	3
in score over the	3
versus days of remdesivir	3
a number of other	3
of ongoing clinical trials	3
was based on the	3
the number of authors	3
we did not want	3
additional barriers relate to	3
of hydroxychloroquine for covid	3
continues to adhere to	3
publication of this article	3
and the need to	3
but not if worn	3
this is a multi	3
hydroxychloroquine with or without	3
five single trials showed	3
patient and public involvement	3
safety data in anti	3
a clinical trial of	3
in malaria chemoprevention in	3
we expect the treatment	3
both the pwd and	3
this revealed that there	3
prevention in cancer patients	3
the possibility of undue	3
be more likely to	3
absence of comprehensive trial	3
ethics approval and consent	3
use of respiratory protection	3
a macrolide for treatment	3
of utmost importance to	3
without a macrolide for	3
things in order to	3
the certainty of evidence	3
in spite of this	3
with the number of	3
within and alongside genv	3
of patients with bubonic	3
difference in score over	3
symptoms of nasal blockage	3
the status of surgical	3
as the number of	3
such external unplanned obstacles	3
the middle east respiratory	3
and clinical characteristics of	3
the trial in the	3
burdensome the task is	3
of comprehensive trial coordination	3
prospect of direct benefit	3
will be compared between	3
acute exacerbation of chronic	3
enrolled in these trials	3
analysis in clinical trials	3
to the control group	3
clinical trials and research	3
can be attributed to	3
the duration of mechanical	3
had no role in	3
reduce the risk of	3
missing completely at random	3
search the platform every	3
were more likely to	3
number of clinical trials	3
a deviated septum and	3
the effect of surfactant	3
personal and professional use	3
study by gautret et	3
as compared with the	3
primary outcome of mortality	3
nasal obstruction associated with	3
in addition to these	3
eligible patients will be	3
of the k th	3
the university of chicago	3
based mitigation measures influence	3
participants will be asked	3
this is especially important	3
of technical requirements for	3
and inform guidance for	3
the research team to	3
will be able to	3
participate in different categories	3
divided by the total	3
analysis on remdesivir versus	3
the current pandemic of	3
guideline for good clinical	3
for handling of missing	3
trials that exclusively enrolled	3
the tablet into their	3
categories of clinical trials	3
born in bradford better	3
under a author funder	3
acute hypoxemic respiratory failure	3
the first edition of	3
the ministry of health	3
international committee of medical	3
the database is updated	3
handbook for systematic reviews	3
randomised controlled trial date	3
evidence of efficacy of	3
preventive treatment with sulfadoxine	3
it is of utmost	3
prevent influenza transmission in	3
not cross the inner	3
for medical research involving	3
ball and three straws	3
ritonavir and recombinant interferon	3
for human research protection	3
will be generated by	3
was to describe the	3
the brain of the	3
a nationwide analysis in	3
the patients in the	3
should be taken to	3
not certified by peer	3
the risk of all	3
used by sick patients	3
treated with a combination	3
the prevention of malaria	3
the assessment of patients	3
were placed on the	3
the lack of relevant	3
lines nor the daris	3
and trial steering committee	3
society and conservation the	3
the lack of a	3
efficient and flexible due	3
was to review the	3
or without a macrolide	3
the scientific community to	3
to reject that hydroxychloroquine	3
and clinical research of	3
the resource utilization in	3
patients in need of	3
for each of the	3
medical staff involved in	3
of clinical trials are	3
the next step in	3
need to be adjusted	3
compared to placebo provided	3
prone positioning with nasal	3
as a part of	3
no standard of care	3
patients who did not	3
is experienced by the	3
to health care professionals	3
analyses may need to	3
can be divided into	3
cannot take it orally	3
number of reported deaths	3
the assessment time points	3
no clinical decision to	3
of the trials reported	3
so the pangolin could	3
of the efficacy of	3
if worn continually during	3
both for patients in	3
of a clinical trial	3
a limited number of	3
olds used an efficient	3
treatment and for researchers	3
adverse events will be	3
hesitancy or inability to	3
cochrane handbook for systematic	3
with or without azithromycin	3
the medical management arm	3
and the need for	3
the treatment group and	3
in different categories of	3
evaluate the efficacy and	3
the same way as	3
the time of the	3
best research approaches are	3
test and four control	3
an impact on the	3
removing the straw directly	3
in the who international	3
pharmacologic treatments for coronavirus	3
vaccines at pandemic speed	3
other critical tasks or	3
wellbeing of participants as	3
use the most efficient	3
as defined by trialists	3
but were underpowered to	3
to be more effective	3
of death and serious	3
was a significant effect	3
of patients admitted to	3
than hand hygiene alone	3
for a randomised controlled	3
and consent to participate	3
the us national institutes	3
at a dose of	3
effect of dexamethasone in	3
many walls and ceilings	3
number of patients to	3
data cleaning and database	3
be recorded in the	3
this pandemic will not	3
the task is experienced	3
management of the trial	3
better understanding of the	3
therapy in patients with	3
this review will continuously	3
baseline to day and	3
the progress of the	3
group will receive the	3
clinical decision to continue	3
are based on in	3
are among the most	3
no role in the	3
visual or acoustic information	3
with a third reviewer	3
in metastatic colorectal cancer	3
china in december is	3
exacerbation of chronic obstructive	3
of randomized clinical trials	3
phase as compared with	3
norwegian national advisory unit	3
changes to the protocol	3
the primary analysis is	3
during the course of	3
outward sloping red lines	3
of dexamethasone on all	3
to be completed by	3
from the patient or	3
agreed to participate in	3
cognitive decline in the	3
and interpretation of data	3
ceilings to bump into	3
will be randomized using	3
is to assess the	3
formal distinction between care	3
total number of straws	3
unexpected serious adverse reactions	3
trials showed statistically significant	3
configuration of the task	3
and a lack of	3
will be performed using	3
experience in treating similar	3
was first detected in	3
vaccines for developing countries	3
available from the corresponding	3
exclude the possibility that	3
viruses such as sars	3
in need of treatment	3
the consolidated standards of	3
of mashhad university of	3
registered clinical trials related	3
or a legal advocate	3
of the nasal septum	3
diagnosis and treatment of	3
the need for the	3
and wellbeing of participants	3
chloroquine diphosphate as adjunctive	3
of acute exacerbation of	3
versus standard care reduced	3
the performance of a	3
be considered when interpreting	3
included in the trial	3
did not want to	3
presented with the task	3
participated in the design	3
nor the conventional naive	3
is the paucity of	3
implications of coronavirus disease	3
for critically ill patients	3
missing data in clinical	3
and ongoing clinical trials	3
for patients in need	3
effective than hand hygiene	3
inform best practice in	3
in light of this	3
all at risks of	3
choice task in which	3
the international society of	3
where there is a	3
terms of timing related	3
both trials were assessed	3
kin or a legal	3
was not certified by	3
in detail in the	3
severe acute respiratory failure	3
adjunctive therapy for patients	3
participants and study personnel	3
low doses of chloroquine	3
novel coronavirus pneumonia in	3
influenza and other respiratory	3
harmonisation of technical requirements	3
may be useful to	3
the united states and	3
showed statistically significant results	3
is informed consent always	3
evaluate the impact of	3
available to outside investigators	3
the use of ensemble	3
on ageing and health	3
consent always necessary for	3
a good enough solution	3
patients hospitalized with severe	3
to adhere to study	3
the novel coronavirus named	3
trial showed evidence of	3
the distinction between care	3
average efficient run length	3
is conducted in accordance	3
reduces the risk of	3
systematic review of randomized	3
and ceilings to bump	3
of the ards network	3
risk of death and	3
of the available information	3
international society of dermatology	3
to continue investigative treatments	3
till today there is	3
trial randomizing participants to	3
in a short period	3
plague around the world	3
and safety of antiviral	3
a larger sample size	3
would have agreed to	3
an urgent need for	3
significant results but were	3
to a large number	3
in response to the	3
two full years from	3
of kin or a	3
participants to dexamethasone versus	3
day and on day	3
and other respiratory viruses	3
clinical trials in order	3
their derivative works on	2
as compared with traditional	2
environment for statistical computing	2
creating a framework for	2
in phase i of	2
d or between d	2
licensed under a creative	2
antiviral efficacy and pre	2
french legislation and ethics	2
the time of hospital	2
nature of the including	2
of the chosen container	2
we learn more about	2
estimates to the right	2
represented by f vs	2
interventions that can be	2
to the vaccine in	2
funding agency in the	2
how living systematic reviews	2
who develop the target	2
people with dementia and	2
of intravenous immunoglobulin for	2
findings are likely to	2
this may be particularly	2
of the randomised evaluation	2
be found in additional	2
the pandemic on study	2
review of safety data	2
used to ensure blinding	2
norwegian association for public	2
recruitment and informed consent	2
of withdrawal will be	2
they have no conflict	2
rapid onset of fever	2
did not respond to	2
of the appropriation literature	2
the virus has quickly	2
a great number of	2
the bayesian approach is	2
to carefully design a	2
between the first case	2
and this needs to	2
will successfully transition from	2
help add to our	2
workers showed that respirators	2
used smell to find	2
learning health research enterprise	2
is the focus of	2
social network analysis of	2
economic impact of the	2
description of negative disconfirmation	2
randomized and have received	2
to identify ways to	2
living in the same	2
has greatly impacted surgical	2
the dyads waiting for	2
the debate on the	2
a randomized multicenter study	2
any history of intranasal	2
for healthcare workers are	2
written informed consent to	2
hydroxychloroquine compared with standard	2
industrysponsored clinical trials has	2
volunteer coordinators from nonprofit	2
masks even less effective	2
instrument and the relative	2
as outlined in fig	2
not directly related to	2
generates a randomisation sequence	2
on hydroxychloroquine versus standard	2
publications related to the	2
we consider that our	2
due to the uncertainty	2
interpretation of data and	2
days of remdesivir on	2
for deaths related to	2
era of precision medicine	2
the resman original data	2
in may by the	2
disease in china clinical	2
of the quintet recruitment	2
informed consent to participate	2
a significance level of	2
the participants in the	2
in the hospital setting	2
a pilot study of	2
third party material in	2
in vaccinees who develop	2
defined as any adverse	2
and reproduction in any	2
this one to ensure	2
prone positioning is a	2
in the us and	2
in the respiratory disease	2
eu health sites health	2
in contemporary drug developing	2
for the analysis of	2
controlled experiment to investigate	2
that were mentioned above	2
uncertainty could cause a	2
is better than the	2
must be given to	2
policy in the us	2
majority of authors in	2
group d will receive	2
streptomycin mg kg twice	2
a new vaccine candidate	2
for intermittent preventive treatment	2
task in which only	2
trials are unlikely to	2
we see that users	2
aim of this randomised	2
individual and volitional users	2
such as the coalition	2
patients to be recruited	2
prevent and treat covid	2
of a treatment benefit	2
versus placebo reduced the	2
we have described the	2
data will be uploaded	2
collected as part of	2
the ability to draw	2
a pressing need for	2
patients with mild to	2
to azithromycin when possible	2
directly below the ball	2
randomized to treatment conditions	2
of treatment for covid	2
and on mechanical ventilation	2
compared versus days of	2
this trial future use	2
decision to submit the	2
treatments due to self	2
can take up to	2
it is essential to	2
will have to be	2
data need to take	2
they will be examined	2
controlled trial is to	2
a bayesian adaptive trial	2
we chose to focus	2
are those that adapt	2
in addressing our research	2
of dementia is exceptional	2
the target study population	2
diagram of included trials	2
be viewed as the	2
and stop dates of	2
preliminary report a trial	2
two reviewers then independently	2
were also interested in	2
be the start of	2
testing was conducted on	2
there are many ways	2
for the second stage	2
of authors in this	2
post hoc pairwise comparisons	2
receives anticoagulation treatment with	2
days of the sponsor	2
are essential for the	2
of an artificial light	2
within and across diverse	2
not at this time	2
the general medical health	2
trials and relevant reviews	2
actions that all stakeholders	2
how to manage clinical	2
the benefits and risks	2
are screened for eligibility	2
to reopen the economy	2
from top to bottom	2
across the two phases	2
this living review is	2
for healthcare workers and	2
the goal is to	2
lung injury and ards	2
the intervention therapy being	2
hunts based on distant	2
to summarize safety data	2
clinical trials on use	2
and disadvantages of various	2
clinical trial transparency is	2
the example of the	2
ischemic stroke and cerebral	2
pandemic such as this	2